Watchlist Price Alert

(PSTV)

NASDAQ: PSTV · Real-Time Price · USD

0.34

0.01 (4.45%)

At close: Jun 09, 2025, 3:59 PM

4.45% (1D)

Bid	0.35
Market Cap	11.25M
AUM	-
NAV	-
EPS (ttm)	-2.78
PE Ratio (ttm)	-0.12
Shares Out	32.72M
Inception Date	Invalid Date

Ask	0.35
Volume	3.75M
Open	0.36
Previous Close	0.33
Day's Range	0.34 - 0.37
52-Week Range	0.24 - 2.40
Holdings	-
Expense Ratio	undefined%

About PSTV

A detailed description of the company is not yet available.

Asset Class undefined

Ticker Symbol PSTV

Inception Date Invalid Date

Provider undefined

Website Fund Home Page

Exchange NASDAQ

Why Price Moved

3 weeks ago

+28.16%

PLUS Therapeutics shares are trading higher. The c... Unlock content with Pro Subscription

1 month ago

-5.22%

Plus Therapeutics shares are trading lower after the company announced it received a Nasdaq non-compliance letter.

News

3 weeks ago · zacks.com

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago.

1 month ago · zacks.com

Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Plus (PSTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.

2 months ago · zacks.com

Plus (PSTV) Upgraded to Buy: Here's What You Should Know

Plus (PSTV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · seekingalpha.com

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants E...

2 months ago · zacks.com

Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.70 per share a year ago.

3 months ago · zacks.com

PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug

The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.

3 months ago · accessnewswire.com

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with...